304am永利集团|·主頁(歡迎您)

Be the most trusted biotech company

2020-09-20

First patient dosed in phase 1 clinical trial of Henlius pertuzumab biosimilar HLX11
2020-09-17

Scientific Innovation for the Benefit of the Patients -Exclusive Interview with Henlius Co-CSO and Senior Vice President of R&D, Dr. Ningshu Liu
2020-09-17

The Updated Multi-Centre Phase 3 Clinical Study Data of Trastuzumab 汉曲优® Released in ESMO
2020-09-09

Henlius Bevacizumab Biosimilar Received NDA Acceptance Notification from NMPA
2020-08-14

China's First Trastuzumab Biosimilar 汉曲优® Approved by NMPA
2020-07-29

Challenge Dilemmas in the Treatment of SCCHN, Henlius Innovative Combination Therapy Dosed the First Patient in a Phase 2 Clinical Trial
2020-07-29

Henlius and Accord Healthcare Receive EMA Approval for Zercepac®, trastuzumab biosimilar
2020-06-24

Cooperation with Accord Upgraded: to Bring High Quality Products to More Patients
2020-06-16

Phase 3 Trial of Henlius Bevacizumab Biosimilar HLX04 in Metastatic Colorectal Cancer Met Study Primary Endpoint